News
20don MSN
The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...
AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this ...
Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.
The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...
Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market in the UK, through a ground-breaking collaboration with AstraZeneca.
Daiichi Sankyo is a commercial-stage biopharmaceutical company that is in strong financial health. As of fiscal 2024, it had a debt/EBITDA ratio of 0.3 times and over JPY 700 billion in cash and ...
Daiichi Sankyo and MSD have broadened their partnership for the global joint development and commercialisation of three DXd-based antibody-drug conjugates (ADCs). DXd is Daiichi Sankyo's ...
Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit as a whole — to educate patients about the drug’s expanded uses. The “Not ...
Additionally, Daiichi Sankyo is banking on its ADC platform to target specific antigens and proteins as it explores more treatment options in its pipeline, including patritumab deruxtecan, ifinatamab ...
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients ...
AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results